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Abstract: Urinary tract infections (UTIs) are among the most common infections requiring
medical attention worldwide. The production of biofilms is an important step in UTIs, not only
from a mechanistic point of view, but this may also confer additional resistance, distinct from
other aspects of multidrug resistance (MDR). A total of two hundred and fifty (n = 250)
Escherichia coli isolates, originating from clean-catch urine samples, were included in this study.
The isolates were classified into five groups: wild-type, ciprofloxacin-resistant, fosfomycin-resistant,
trimethoprim-sulfamethoxazole-resistant and extended spectrum β-lactamase (ESBL)-producing
strains. The bacterial specimens were cultured using eosine methylene blue agar and the colony
morphology of isolates were recorded. Antimicrobial susceptibility testing was performed using
the Kirby–Bauer disk diffusion method and E-tests. Biofilm-formation of the isolates was carried
out with the crystal violet tube-adherence method. n = 76 isolates (30.4%) produced large colonies
(>3 mm), mucoid variant colonies were produced in n = 135 cases (54.0%), and n = 119 (47.6%) were
positive for biofilm formation. The agreement (i.e., predictive value) of mucoid variant colonies in
regard to biofilm production in the tube-adherence assay was 0.881 overall. Significant variation
was seen in the case of the group of ESBL-producers in the ratio of biofilm-producing isolates.
The relationship between biofilm-production and other resistance determinants has been extensively
studied. However, no definite conclusion can be reached from the currently available data.
Keywords: urinary tract infections; uropathogen; Escherichia coli; biofilm; colony morphology;
antibiotic; resistance; crystal violet
1. Introduction
The global burden of diseases has shown considerable changes in the last century. Despite
global trends due to demographic and epidemiological transitions, and the more pronounced role of
non-communicable illnesses, infectious pathologies are still an important factor for morbidity and
mortality [1]. Among these infectious diseases, urinary tract infections (UTIs) are some of the most
common illnesses caused by pathogenic microorganisms, predominantly by facultative Gram-negative
bacteria [2–4]; the most common causative agents of UTIs are the members of the Enterobacterales
Diseases 2020, 8, 17; doi:10.3390/diseases8020017 www.mdpi.com/journal/diseases
Diseases 2020, 8, 17 2 of 11
order [5,6]. More specifically, the principal cause of UTIs (>90%) are uropathogenic Escherichia coli
(UPEC) and uropathogenic Klebsiella pneumoniae (UPKP), while other members of the order are
represented to a lesser extent [7,8]. These infections account for 10–30% of infections in community
settings and 25–60% of nosocomial infections overall (predominantly due to catheter-associated
infections), representing a serious economic and public health issue for healthcare infrastructures [9,10].
Depending on the extent of the infection, UTIs may affect the tissues of the lower urinary tract, urethra,
bladder and the kidneys, and be classified either as uncomplicated or complicated infections; in severe
cases, UTIs may be the sources of bacteremia and urosepsis [11]. UTIs are associated with important
societal and monetary considerations: they are associated with approximately 10 million general
practitioner (GP) visits, 1.5 million emergency room visits and 300,000 hospital admissions in the
United States alone [12]. The subsequent costs of UTIs for national economies (including losses due to
sick leave, hospital admissions and pharmacotherapy) may be pronounced, estimated to be as high as
USD 6 billion [13].
The therapy of UTIs largely depends on the anatomical regions affected (acute uncomplicated
cystitis vs. pyelonephritis), the anamnestic data of the patients (e.g., age, gender, underlying
conditions, pregnancy, hypersensitivity) and the results of culture/susceptibility data, if available [14,15].
Based on current international guidelines, nitrofurantoin, fosfomycin, trimethoprim/sulfamethoxazole
and mecillinam are recommended first-line agents for the therapy of uncomplicated UTIs [14–16].
In case of complicated infections or patient characteristics for complicated UTIs, drug allergies or
extensive resistance to the abovementioned drugs, third generation cephalosporins, carbapenems
and aminoglycosides may also be considered [17]. Fluoroquinolones have previously been used as
first-line agents in the therapy of UTIs. However, due high levels of resistance in Gram-negative
bacteria, the concept of “collateral damage” (affecting the gastro-intestinal and vaginal flora) and
the subsequent risk of Clostridioides difficile infections (CDIs) and recent developments in the adverse
events associated with these drugs (including the “black box” warning labels added by the Food and
Drug Administration), the importance of these agents has decreased significantly, only to be used in
well-defined indications [18,19].
One of the most important issue associated with the therapy of UTIs is the emergence and
spread of multidrug-resistant (MDR) bacterial strains-owing to a plethora of different resistance
mechanisms-severely limiting therapeutic alternatives for clinicians [20–22]. This is especially
daunting, if urinary pathogens also possess intrinsic resistance mechanisms or patients have some
underlying conditions [8,23]. High levels of resistance against urinary antibiotics have been reported
in Gram-negative bacteria in regions where no restrictions were introduced to their use in the
community [24]. In addition to these resistance mechanisms, the production of biofilms is another
major concern, often leading to therapeutic failure [25]. Biofilms are aggregates of bacterial communities
inside an extracellular matrix, composed from exopolysaccharides (EPS), proteins and nucleic acid
produced by the multiple bacterial species [26]. Biofilms allow for bacterial communities to attach to
various inanimate and in vivo environments, and provide protection for these bacteria from harsh
environmental conditions and noxious agents, such as antibiotics [25,26]. In fact, the minimal inhibitory
concentration of antibiotics against bacteria embedded in biofilms may be 101–104-times higher,
than against planktonic cells [27]. The eradication of biofilm-embedded pathogens in vivo is still
an important concern, as there are no specific drugs available for the eradication of these bacteria
in infections [28]. The composition of biofilms is inherently heterogenous (including physiological
heterogeneity, genetic variability and stochastic events in gene expression), which makes it difficult
to study them in experimental conditions. Nevertheless, there are various methods available for
their characterization, including staining methods, chromogenic and experimental media, plate-based
methods evaluated by spectrophotometric measurements, electron microscopy and flow chamber
systems [25–28]. These methods vary considerably in their reproducibility, price and the adaptability
of the resulting data to in vivo conditions; nevertheless, due to the significance of biofilm-production
in clinical syndromes and antibiotic non-susceptibility, all of them are frequently used [25–30].
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The role of biofilm-formation during the pathogenesis of UTIs (especially in catheter-associated
infections) has been extensively studied: production of this extracellular matrix aids in the attachment,
provides protection against the sheer forces in the urinary tract and promotes bacterial persistence and
chronicity [29,30].
Recently, several studies aimed to assess the relationship between the phenotypic characteristics
of bacterial pathogens, biofilm-formation and antibiotic-resistance [31]. However, these studies
have often provided conflicting results. The aim of our present study was to assess the potential
correlation between the resistance characteristics of UPEC species and their biofilm-forming capacity
in laboratory-based study.
2. Materials and Methods
2.1. Collection of Isolates
A total of two hundred and fifty (n = 250) E. coli isolates, which were kindly provided by various
Hungarian hospitals, were included in this study. The isolates originated from clean-catch urine samples
from patients with laboratory-confirmed UTIs. The n = 250 isolates included wild-type/pan-susceptible
strains (control group), strains resistant to ciprofloxacin (CIP group), strains resistant to fosfomycin
(FOS group), strains resistant to trimethoprim-sulfamethoxazole (SXT group) and extended spectrum
β-lactamase (ESBL)-producers in equal measure (n = 50 strains in each group). The isolates in
the latter four groups were selected specifically on the basis that they are not resistant to other
agents in any of the other tested antibiotic groups. During our experiments, E. coli ATCC 25298
(pan-susceptible, “wild strain”, strong biofilm-producer [32]), E. coli ATCC 35218 (blaTEM-1-producer,
weak biofilm-producer [33]; obtained from the American Type Culture Collection, Manassas, VI,
USA), E. coli 15/12569 (resistant to ciprofloxacin; MICciprofloxacin = 2 mg/L), E. coli 17/47012 (resistant to
fosfomycin; MICfosfomycin = 64 mg/L) and E. coli 16/30098 (resistant to trimethoprim-sulfamethoxazole;
MICSXT = 16 mg/L) were used as control strains (clinical isolates obtained from various hospitals).
2.2. Bacterial Identification
Identification of E. coli isolates was carried out using matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Daltonics, Bremen, Germany). Bacterial cells
from fresh overnight cultures were transferred to a stainless-steel target. An on-target extraction was
performed by adding 1µL of 70% formic acid prior to the matrix. After drying at an ambient temperature,
the cells were covered with 1 µL matrix (α-cyano-4-hydroxy cinnamic acid in 50% acetonitrile/2.5%
trifluoro-acetic acid; Bruker Daltonics, Bremen, Germany). MALDI-TOF MS measurements were
performed by the Microflex MALDI Biotyper (Bruker Daltonics, Bremen, Germany) in positive linear
mode across the m/z range of 2 to 20 kDa; for each spectrum, 240 laser shots at 60 Hz in groups
of 40 shots per sampling area were collected [34]. The MALDI Biotyper RTC 3.1 software (Bruker
Daltonics, Bremen, Germany) and the MALDI Biotyper Library 3.1 were used for spectrum analysis.
Based on spectrum analysis, a log(score) value was provided, indicating the reliability of MALDI-TOF
MS identification: a log(score) <1.69 showed unreliable identification, 1.70–1.99 corresponded to
probable genus-level identification, 2.00–2.29 corresponded to reliable genus-level identification, while
a score ≥2.30 corresponded to reliable species-level identification [31]. All isolates included in the
study were re-identified as E. coli before further experiments.
2.3. Colony Characteristics
The bacterial specimens were cultured using eosine methylene blue (EMB) agar (bioMérieux,
Marcy-l’Étoile, France) plates. To record colony morphology of the bacterial isolates, EMB plates were
inoculated and incubated at 37 ◦C for 24 h, at aerobic atmosphere. After the incubation period, colony
morphologies were assessed visually (for size, mucoid nature and lactose-fermentation) and these
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data were recorded. Colonies were considered small if their side was below 3 mm, or large if their size
was >3 mm [33].
2.4. Antimicrobial Susceptibility Testing, Resistance Detection
Antimicrobial susceptibility testing (AST) was performed either using the Kirby–Bauer disk
diffusion method and E-tests (Liofilchem, Abruzzo, Italy) on Mueller–Hinton agar (MHA) plates. The
interpretation of the results was based on EUCAST breakpoints v. 9.0. (http://www.eucast.org). E. coli
ATCC 25298 was used as a quality control strain. Screening for ESBL-production was carried out using
cefpodoxime 10 µg disks; the screening test was considered positive, if the inhibition zone diameter
was <21 mm [35]. Verification of ESBL-production was performed using the AmpC-ESBL Detection
Set (MAST Diagnostica GmbH, Reinfeld, Germany) [7].
2.5. Assessment of Biofilm-Production by the Tube-Adherence Method
Biofilm-formation of the isolates was carried out in the tube-adherence method described
previously [36]. Briefly, glass tubes containing 1 mL of sterile trypticase soy broth (bioMérieux,
Marcy-l’Étoile, France) were inoculated with 1 µL of the overnight culture of a respective bacterial
strain. The tubes were then incubated statically for 24 h at 37 ◦C. Verification of planktonic growth was
observed visually. After the incubation period, the supernatant was then discarded, the adhered cells
were rinsed three times with phosphate buffer saline (PBS; Sigma-Aldrich; Budapest, Hungary) and the
tubes were patted dry on a paper towel. The contents of the tubes were treated with a 1 mL solution of
0.1% crystal violet (CV; Sigma-Aldrich; Budapest, Hungary) to stain the adhered biomass; the tubes
were incubated for 3 h at room temperature with the staining solution. The crystal violet solution was
then discarded and the tubes were again rinsed three times with PBS and the tubes were patted dry on
a paper towel. Biofilm-formation was observed visually; the appearance of visible biofilm lining at the
bottom and on wall of the glass tubes were considered positive for biofilm-production [36].
2.6. Statistical Analysis
Descriptive statistical analysis (including means and percentages to characterize data) was
performed using Microsoft Excel 2013 (Microsoft Corp.; Redmond, WA, USA). Additional statistical
analyses were performed with IBM SPSS Statistics for Windows 24.0 (IBM Corp., Armonk, NY,
USA), using the χ2-test. p values < 0.05 were considered statistically significant. Additionally,
consistency-assessment was also performed between the results of the colony morphology and
biofilm-production studies [31].
2.7. Ethical Considerations
Clinical, personal and epidemiological data pertaining to the affected patients was not collected
or provided during the study, bacterial isolates were only identifiable based on their serial number;
therefore, our present study was not subject to ethics review.
3. Results
3.1. Association of Antibiotic Resistance with Colony Characteristics in Uropathogenic E. coli (UPEC)
Out of the n = 250 E. coli isolates included in this study, n = 76 isolates (30.4%) produced large
colonies (>3 mm): n = 24 in the control group, while this was n = 11 (p = 0.0064; χ2 = 7.428; degrees
of freedom [DOF]: 1) in the CIP-group, n = 13 (p = 0.023; χ2 = 5.191; DOF: 1) in the FOS-group and
n = 14 (p = 0.039; χ2 = 4.245; DOF: 1) in both the SXT- and ESBL-producer group. The emergence of
large-colony producing isolates was significantly lower in all antibiotic-resistant groups, compared to
the wild type isolates (Figure 1).
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(UPEC).
Mucoid variant colonies were produced in n = 135 cases (54.0%): in the control group, 33/50 isolates
showed mucoid colonies, while this ratio was 28/50, 29/50 and 29/50 for the CIP-group, SXT-group and
the F S-group, respectively (p > 0.05 in all cases) (Figure 1). Significant variation was seen only in
the case of the group of ESBL-producers (16/50 isolates; p < 0.0001; χ2 = 11.561; DOF: 1). Most E. coli
isolates (98.8%) showed lactose-fermentation when observed on EMB-agar after 24 h, only n = 3 (one
in the ESBL-group and two in the CIP-group) lactose-non fermenting isolates were noted. Among
the control strains, E. coli ATCC 25298 presented with small, mucoid colonies, E. coli ATCC 35218,
E. coli 15/12569, E. coli 17/47012 with small, non-mucoid colonies, while E. coli 16/30098 with large,
non-mucoid colonies. All control strains were lactose-fermenters.
3.2. Association of Antibiotic Resistance with Biofilm-Formation in UPEC
Out of the tested isolates, n = 119 (47.6%) were positive for biofilm formation in the tube-adherence
assay: in the control group, 30/50 isolates showed biofilm-formation, while this ratio was 27/50,
26/50 and 22/50 for the CIP-group, SXT-group and the FOS-group, respectively (p > 0.05 in all cases).
Pronounced differences were observed for the ESBL-group, where only 14/50 isolates produced biofilm
in this assay (p = 0.0013; χ2 = 10.39; DOF: 1) (Figure 1). The agreement (i.e., predictive value) of mucoid
variant colonies in regard to biofilm production in the tube-adherence assay was 0.881 or 88.1% overall
(control: 0.909, CIP: 0.964, SXT: 0.897, FOS: 0.759, ESBL: 0.875). Among the control strains, E. coli ATCC
25298 was positive for biofilm-formation, while all other control strains were negative.
4. Discussion
UTIs caused by drug-resistant E. coli is an important clinical concern, affecting a large amount of
patients, both in outpatient and in hospital settings [37]. Recent literature reports highlight that the
resistance levels of uropathogenic E. coli against fluoroquinolones, trimethoprim-sulfamethoxazole
and third generation cepalosporins in Iran is ranging between 30–60%, 40–80% and 15–66% [38];
while this ratio in Hungary is between 20–40%, 5–15%, 25–40%, 10–30%, and 10–15% for
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fluoroquinolone, nitrofurantoin, trimethoprim-sulfamethoxazole, third generation cephalosporin,
and fosfomycin-resistant isolates, respectively [21]. Catheter-associated UTIs (CA-UTIs) are the
most nosocomial infections worldwide, leading to high costs for the healthcare-providers and
decreased quality of life for the affected patients [9,39]. The production of biofilms is ubiquitous
in the environment and has been described in 65% of human infections (affecting patients from all
backgrounds and in all age groups); therefore, they present an important unresolved issue for both
clinicians and researchers [40]. The characteristic of producing EPS matrix also strongly correlates to
the proclivity of these bacteria to become nosocomial pathogens (K. pneumoniae, Pseudomonas aeruginosa,
Acinetobacter spp., Staphylococcus aureus among others), surviving in the harsh physical environments
of hospitals [41–44]. Biofilms also contribute to bacterial antibiotic resistance in an indirect manner,
by augmenting the pharmacokinetic properties (i.e., the ability of these drugs to penetrate and reach
the microorganisms in effective concentrations) of the anatomical region [25–30]. The production of
biofilms also correspond to transcriptional changes in these bacteria (often mediated by quorum-sensing
[QS]-based mechanisms); this may lead to the differential expression of various virulence factors,
metabolic end-products or antibiotic-resistance determinants [45]. Bacterial cell–cell communication
(or QS) is the phenomenon of transcriptional changes in bacteria due to reaching a threshold in
surrounding bacterial population density, mediated by secreted compounds termed autoinducers [45].
As biofilm-formation is a mutually-beneficial, cooperative behavior to enhance the survival of the
overall bacterial population, it is not surprising that genes involved in biofilm-development are
QS-mediated, highlighting the close interdependence of the two mechanisms [45,46]. Comparisons
between biofilm and planktonic cells are difficult to make due to the intrinsic difference between the
two modes of growth, such as compositional differences in biomass. These evolutionary trade-offs
may explain differential resistance-trends in the same species of biofilm-producing and non-producing
bacteria during in vitro testing [46].
In our present study, n = 250 E. coli isolates were characterized, using phenotypic tests to ascertain
a possible correlation between resistance and biofilm-formation. Our isolates were grouped based on
their distinct resistance mechanisms and compared to the control group, containing wild-type E. coli.
62.0% of isolates overall produced mucoid colonies, and almost half (47.6%) of the tested isolates
produced biofilm in the tube-based assay. Based on our results, the predictive power of mucoid-variant
colonies for positivity in the biofilm-assay was 88.1%; our results contrast the findings of Whelan et al.,
who noted 50 out of 62 (81%) tested E. coli isolates as strong biofilm-producers and a much lower (4%)
predictive power between mucoid-type E. coli on Cysteine Lactose Electrolyte Deficient (CLED) agar
and strong biofilm-formation [31]. Lajhar et al. have come to similar conclusions, when studying the
biofilm-formation of E. coli O26 pathotypes in different in vitro settings and on various surfaces [47].
Significant differences in the share of mucoid colony-forming and biofilm-producing strains E. coli
were only observed in the group of ESBL-producers (positivity was much lower, compared to the
control group), while such differences were not shown for the CIP, FOS and SXT-groups. On the other
hand, differences in colony size were noted between the control group all other isolates, showing
any kind of phenotypic resistance. The ratio of lactose-non-fermenting E. coli in our study was 1.2%
(n = 3), which is similar to the global prevalence of lactose-negative strains (0–5%) reported in other
studies [48]. The number of lactose-negative isolates in the present study was too low to provide
any relevant conclusions on the topic. Nevertheless, in another study by Gajdács et al., the antibiotic
susceptibilities of lactose-fermenting and non-fermenting E. coli from UTIs were compared during a
5-year study period in Southern Hungary. In this study, it was found that the resistance rates of lactose
non-fermenters were higher for fluoroquinolones, fosfomycin and nitrofurantoin in both inpatients
and outpatients [49].
Although the correlation between biofilm-production and the expression of non-biofilm-based
antibiotic resistance has been a topic of pronounced interest in the last several years, the
literature surrounding this topic contains conflicting data, therefore definite conclusions cannot
be drawn as of now. In a study by Dumaru et al., the correlation between the MDR phenotype,
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ESBL- and carbapenemase-production and biofilm-formation were assessed in gut bacteria and
non-fermenters [36]; in their report, 62.7% of isolates were biofilm-producers and there was strong
association found between the MDR-status, carbapenemase-production and biofilm-production,
while this was not shown for ESBL-positivity. Nirwati et al. studied the potential association of
resistance and biofilm-production in n = 167 K. pneumoniae isolates: 55.7% of their tested isolates
were biofilm-producers (moderate or strong), and in the non-biofilm-producing group, resistant
isolates (both non-MDR and MDR) were less common, then among biofilm-positive isolates [50].
Avila-Novoa et al. studied the correlation between biofilm-formation and MDR in A. baumannii using
phenotypic and genotypic methods; in their study, 73.3% of isolates were biofilm-producers based on
the Congo red agar method and showed a 73.3% susceptibility to cefepime and a 53.3% susceptibility to
ciprofloxacin. Nevertheless, their study did not find any clear association between biofilm-production
and susceptibility [51].
The study of Cepas et al. included various Gram-negative bacteria (E. coli, K. pneumoniae,
and P. aeruginosa), which found no direct link between possessing the MDR phenotype and
biofilm-production. However, individual associations with resistance to several antibiotics (gentamicin
and ceftazidime in E. coli, ciprofloxacin in P. aeruginosa and colistin in K. pneumoniae) and
biofilm-positivity were noted [52]. In the study performed by Qi et al. the phenotypic and
genotypic characterization and typing of A. baumannii isolates were performed, in the context of
biofilm-production [53]; in their analysis of n = 272 isolates, they revealed that non-MDR isolates
were more common in biofilm-non-producers. The correlation of meropenem-resistance and the
ability to form biofilms were assessed by Perez et al. [54], where an inverse relationship was identified
between carbapenem non-susceptibility and biofilm-production. These results were further verified
by Mustafer et al., where P. aeruginosa strains showing imipenem-resistance (owing to a variety of
resistance mechanisms) [55]. In addition, Fábréga et al. also showed an inverse relationship between
biofilm-production and quinolone-resistance, in the context of Salmonella enterica [56]. In contrast,
Gurung et al. showed that MDR P. aeruginosa and A. baumanni strains were significantly more common
among strong biofilm-producers, compared to the non-biofilm group [57]. Regarding UPEC strains,
the article published by Neupane et al. showed that biofilm-production in ESBL-producing E. coli
correlated with more extensive biofilm-production, compared to susceptible isolates [58], while Soto
et al. noted an inverse correlation between biofilm-production and quinolone resistance [59]. In a
longitudinal cohort study, Bartoletti et al. found that in their “Chronic Bacterial Prostatitis (CBP)
population”, biofilm-producing bacteria were commonly found and had a significant negative impact
on the clinical response to the adequate antibiotic therapy [60]. Thus, it may be concluded that there
may be some kind of association between the expression of antibiotic-resistance-determinants and
biofilm-production. However, the exact nature of that relationship still needs further studies [61,62].
5. Conclusions
UTIs are one of the most common infections requiring medical attention worldwide. The therapy
of UTIs caused by E. coli may be hindered by the extensive resistance levels associated with these agents.
The production of biofilms is an important step in UTIs, not only from a mechanistic/pathogenetic point
of view, but this may also confer additional resistance through a mechanism distinct from other aspects
of MDR. In fact, the relationship between biofilm-production and other resistance determinants have
been extensively studied. However, no definite conclusion can be reached by the currently available
data. Our study aims to provide additional data to the present knowledge base on the topic. While
the phenotypic characteristics of UPEC colonies were shown to be affected by the presence of any
resistance mechanisms (compared to wild-type strains), this statistical association was not shown
in the case of biofilm-production, except for the case of ESBL-producers, where biofilm-producers
were significantly less common. While other studies noted associations between the MDR phenotype
or resistance against various antibiotics and biofilm-production, only a numerical, but not statistical
difference was shown in our study. In contrast, while other studies showed poor correlation between
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colony characteristics and biofilm-production, a >85% agreement was seen during our experiments.
The mechanisms behind these possible associations need to be further characterized. However, it may
be postulated that evolutionarily-conserved mechanisms of expressional or metabolic “switching”
may explain the differential susceptibilities among biofilm-positive and negative strains, aiming
to accommodate bacteria to the dynamic changes observed in vivo. As a future aim, our studies
could be extended to other relevant bacterial strains of importance in UTIs (e.g., K. pneumoniae,
S. aureus, S. saprophyticus, Enterococcus spp.) where antibiotic resistance has shown to be a major
concern, to ascertain a possible correlation of biofilm-formation and the susceptible/resistant phenotype.
In addition, other budget-friendly experimental model systems may also be utilized in these studies.
In summary, our results have shown no relevant association between biofilm-production and
resistance to several antibiotics, while ESBL-production was a predictor of lower prevalence of
biofilm-producing strains. On the other hand, a significant, but not complete agreement was noted
between biofilm-positivity and the phenotype of mucoid variant colonies.
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